Riabni
Rituximab biosimilar developed by Amgen, development code ABP 798. Reference product MabThera (Rituxan in the United States).
About Riabni
Riabni is Amgen's rituximab, approved in the United States in December 2020. Its Canadian approval was cancelled after marketing. Amgen has not filed it in Europe.
Status by market
United States · Riabni
US Food and Drug AdministrationApprovedEuropean Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada · Riabni
Health CanadaWithdrawnIndia
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Riabni holds an approval, these are the other rituximab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| FDA | 3 | Celltrion (Truxima / Blitzima), Dr. Reddy's Laboratories (Zimrixby / Ituxredi), Pfizer (Ruxience) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Amgen: Amjevita / Amgevita, Avsola, Bkemv / Bekemv, Kanjinti, Mvasi, Pavblu, Wezlana / Wezenla.
Chronology
- FDADec 2020Approved by FDA as Riabni
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)S022Health Canada, Drug Product Database data extract (active and inactive product files, biosimilar table) Primary (regulator)
Planning rituximab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant